Moderna, Inc. (MRNA)

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Address

325 BINNEY STREET

CAMBRIDGE, MA 02142

Founded

2010

Number of Employees

5,600

Website

http://www.modernatx.com

Buyback

Buyback Data	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Average
$ Amount Purchased ($ in 000s )	-	-	-	-	-	-	-	$857,234	$3,328,766	$1,151,913	-	$1,779,304
Average Price	-	-	-	-	-	-	-	$245.76	$142.83	$143.12	-	$153.20
# Shares Purchased	-	-	-	-	-	-	-	3,488,142	23,305,186	8,048,761	-	11,614,030

Buyback Performance	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Average
Total Return to Date	-	-	-	-	-	-	-	-72.3%	-52.4%	-52.5%	-	-55.6%
S&P 500 Return to Date	-	-	-	-	-	-	-	31.7%	37.3%	31.3%	-	33.4%
Excess Total Return	-	-	-	-	-	-	-	-104.0%	-89.7%	-83.8%	-	-89.0%
Quartile Rank
Percentile Rank	-	-	-	-	-	-	-	5%	11%	6%	-	12%

Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.

Showing content blurred. Create an account to see more.

Insider Transactions

Filters

Keyboard Shortcuts: Show (a) | Close (Esc)

People also followed

BANCEL STEPHANE

Moderna, Inc.